Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Kingdom of Saudi Arabia.
Clinical Pathology and Pharmaceutics Department, Faculty of Pharmacy, Taif University, Taif, Kingdom of Saudi Arabia.
In Vivo. 2022 May-Jun;36(3):1497-1502. doi: 10.21873/invivo.12857.
BACKGROUND/AIM: Breast cancer (BC) is among the most widespread malignant tumors in women. In the current study, we evaluated the role of miR-31 in BC patients and its relation to the different prognostic, clinical, and pathological features.
MiR-31 levels were determined by RT-PCR in BC and adjacent normal breast tissues from 100 BC patients. BC diagnosis was established through histopathological examinations. The expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) receptor in all tumors was determined using immunohistochemistry.
MiR-31 expression was reduced in BC tissues relative to adjacent healthy breast tissue (mean levels were 0.93 and 7.2, respectively). Also, the low expression of miR-31 in BC patients was significantly correlated with adverse clinical and pathological features such as: young patient's age, premenopausal status, infiltrative lobular carcinoma, ER and PR negative tumors, HER2 positive tumors, and advanced clinical stage.
MiR-31 was expressed at low levels in BC tissues and correlated with adverse clinical and pathological features, and poor survival.
背景/目的：乳腺癌（BC）是女性中最常见的恶性肿瘤之一。在本研究中，我们评估了 miR-31 在 BC 患者中的作用及其与不同预后、临床和病理特征的关系。
通过 RT-PCR 测定了 100 例 BC 患者的 BC 和相邻正常乳腺组织中的 miR-31 水平。BC 诊断通过组织病理学检查确定。使用免疫组织化学检测所有肿瘤中雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体 2（HER2）受体的表达。
与相邻健康乳腺组织相比，BC 组织中 miR-31 的表达降低（平均水平分别为 0.93 和 7.2）。此外，BC 患者中 miR-31 的低表达与不良的临床和病理特征显著相关，如：年轻患者的年龄、绝经前状态、浸润性小叶癌、ER 和 PR 阴性肿瘤、HER2 阳性肿瘤和晚期临床分期。
miR-31 在 BC 组织中表达水平较低，与不良的临床和病理特征以及不良预后相关。
